Sugi Predict

Sugi Predict / Targets / POT1

POT1

Protection of telomeres protein 1 · Q9NUX5 · POT1 on Sugi Atlas →

100 patent compounds predicted against POT1, 80 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL14355612 SCHEMBL14355612 0.81 4/20
SCHEMBL14355590 SCHEMBL14355590 0.78 4/20
SCHEMBL14355573 SCHEMBL14355573 0.76 4/20
SCHEMBL14355659 SCHEMBL14355659 0.74 4/20
SCHEMBL13989204 SCHEMBL13989204 0.72 4/20
SCHEMBL14355569 SCHEMBL14355569 0.72 4/20
SCHEMBL5342792 SCHEMBL5342792 0.55 4/20
SCHEMBL14355614 SCHEMBL14355614 0.86 3/20
SCHEMBL14355624 SCHEMBL14355624 0.78 3/20
SCHEMBL31237628 SCHEMBL31237628 0.74 3/20
SCHEMBL14355630 SCHEMBL14355630 0.74 3/20
SCHEMBL14355591 SCHEMBL14355591 0.71 3/20
SCHEMBL14355668 SCHEMBL14355668 0.71 3/20
SCHEMBL14355623 SCHEMBL14355623 0.71 3/20
SCHEMBL14355625 SCHEMBL14355625 0.71 3/20
SCHEMBL13989206 SCHEMBL13989206 0.71 3/20
SCHEMBL14626194 SCHEMBL14626194 0.71 3/20
SCHEMBL13989194 SCHEMBL13989194 0.70 3/20
SCHEMBL31237593 SCHEMBL31237593 0.70 3/20
SCHEMBL13989199 SCHEMBL13989199 0.68 3/20

Clinical trials — most relevant to POT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switch to Maraviroc + Integrase Inhibitor PHASE3COMPLETED
Low-Dose Danazol for the Treatment of Telomere Related Diseases PHASE2COMPLETED
Danazol for Genetic Bone Marrow and Lung Disorders PHASE1/PHASE2COMPLETED
Nandrolone Decanoate in the Treatment of Telomeropathies PHASE1/PHASE2COMPLETED
Danazol for Treatment of Cytopenias in Patients With Cirrhosis PHASE2RECRUITING
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation PHASE2ACTIVE_NOT_RECRUITING
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma PHASE1WITHDRAWN
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
INVAC-1 Anti-Cancer hTERT DNA Immunotherapy PHASE1COMPLETED
Plasmapheresis for Treatment of Age-Related Frailty EARLY_PHASE1UNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Aerobic Exercise and Telomere Length in Patients With Heart Failure. nanUNKNOWN
Telomere Disclosure and Impact on Psychological Distress and Health Behaviors nanCOMPLETED
Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique nanUNKNOWN
Telomere and Telomerase nanWITHDRAWN
Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder nanUNKNOWN
Telomere Repair Gene Mutation in Inflammatory Bowel Disease nanCOMPLETED
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals nanUNKNOWN
Body Awareness and Aerobic Exercise: Telomere Impact nanCOMPLETED
Mitochondrial DNA Copy Number and Leukocyte Telomere Length as Biomarkers in Type 2 Diabetic Patients nanUNKNOWN
Association of Leucocyte Telomere Length With DPAS Score in Skin Aging nanRECRUITING
Genetic Biomarkers of Executive Stress nanCOMPLETED
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes nanRECRUITING
Anti-age Dietary Supplements in Healthy Older Adults: the proBNPage Reduction Trial nanUNKNOWN
Self-Directed Biological Transformation Initiative nanCOMPLETED
The Impact of an Evidence-Based Parenting Service on Maternal Sensitivity and Infant Cellular Aging in a Population of Under-Resourced Families nanRECRUITING
Telomere Associated Variables (TAVs) in Prostate Cancer nanCOMPLETED
Telomerase Activator and Retinal Amyloid nanCOMPLETED
Influence of Prostate Cancer Radiation on Aging nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a POT1 binder may also engage these)

ProteinNameSimilarity
Q95K48 — 1.000 Q95K48 →
Q96MZ0 — 0.927 Q96MZ0 →
Q5F450 — 0.927 Q5F450 →
Q92545 — 0.927 Q92545 →
PTAR1 Protein prenyltransferase alpha subunit repeat-containing protein 1 0.926 landscape →
Q9CQC8 — 0.924 Q9CQC8 →
Q25BN1 — 0.924 Q25BN1 →
O43913 — 0.923 O43913 →
B2RY83 — 0.922 B2RY83 →
Q8IUI8 — 0.922 Q8IUI8 →
Q86XW9 — 0.922 Q86XW9 →
Q6P6P7 — 0.921 Q6P6P7 →
Q5RDU4 — 0.921 Q5RDU4 →
P54277 — 0.920 P54277 →
Q0VCJ8 — 0.919 Q0VCJ8 →
METTL16 RNA N(6)-adenosine-methyltransferase METTL16 0.919 landscape →
Q8WWQ2 — 0.918 Q8WWQ2 →
Q6TUI4 — 0.918 Q6TUI4 →
Q5ZIL9 — 0.918 Q5ZIL9 →
Q9NW38 — 0.918 Q9NW38 →
PARP6 Protein mono-ADP-ribosyltransferase PARP6 0.918 landscape →
Q5ZJB7 — 0.917 Q5ZJB7 →
O70472 — 0.917 O70472 →
Q9EPL4 — 0.917 Q9EPL4 →
Q8C525 — 0.917 Q8C525 →
Q504Q3 — 0.917 Q504Q3 →
Q9H1A3 — 0.917 Q9H1A3 →
Q9UPY3 — 0.917 Q9UPY3 →
Q5RES2 — 0.916 Q5RES2 →
Q96IK5 — 0.916 Q96IK5 →